LABT: LABT names David Armstrong as Study Chair for Phase 2a Nu-3 iDFU trial

AI Summary

Lakewood-Amedex (NASDAQ: LABT) appointed David G. Armstrong, a globally recognized diabetic foot expert, as Study Chair and Scientific Advisor for its Phase 2a proof-of-concept trial of topical Nu-3 gel in infected diabetic foot ulcers. The Phase 2a will evaluate safety and efficacy of three topical concentrations (2%, 5% and 10%) to support a larger Phase 2b, and Armstrong's involvement could strengthen trial design, enrollment and clinical credibility. The company did not report clinical data or timing — this is a leadership/operational milestone rather than a readout.

Positives

Appointed world-renowned diabetic foot expert David G. Armstrong as Study Chair and Scientific Advisor
Phase 2a is a proof-of-concept trial testing three topical Nu-3 doses (2%, 5%, 10%) to evaluate safety/efficacy and support Phase 2b
High-profile investigator likely to aid trial design, recruitment and external credibility

Negatives

No clinical efficacy or safety data disclosed in the announcement
No trial start dates, timelines or enrollment targets provided
Progression to later trials and regulatory outcomes remain uncertain (forward-looking risks)